45th week of 2014 patent applcation highlights part 31 |
Patent application number | Title | Published |
20140328728 | PLASMA GENERATION DEVICE - There is provided a plasma generation device capable of suppressing arc discharge in which discharge is localized to cause a high temperature, and allowing atmospheric discharge plasma to be stably generated with a high generation efficiency in a low temperature at about a room temperature without being spatially biased. The plasma generation device arranged with a plurality of electrodes facing each other includes a discharge position control unit, which is arranged between each of the plurality of electrodes, and is formed by containing an inverse characteristic material composed of a fluid having polarizability and a property that dielectric constant decreases with an increase in temperature, in a container formed of a dielectric material, wherein the inverse characteristic material is spaced apart from each of the plurality of electrodes. | 2014-11-06 |
20140328729 | Apparatus for Preparing a Material of a Battery Cell - A continuous process for producing a material of a battery cell using a system having a mist generator, a drying chamber, one or more gas-solid separators and a reactor is provided. A mist generated from a liquid mixture of two or more metal precursor compounds in desired ratio is dried inside the drying chamber. Heated air or gas is served as the gas source for forming various gas-solid mixtures and as the energy source for any reactions inside the drying chamber and the reactor. One or more gas-solid separators are used in the system to separate gas-solid mixtures from the drying chamber into solid particles mixed with the metal precursor compounds and continuously feed the solid particles into the reactor for further reaction to obtain final solid material particles with desired crystal structure, particle size, and morphology. | 2014-11-06 |
20140328730 | CIRCULATION TYPE GASIFICATION FURNACE - A circulation type gasification furnace is provided with: a gasification furnace that turns a fluidized medium into a fluidized bed or moving bed, and produces gasification gas by gasifying a gasification raw material injected into the fluidized medium; a combustion furnace that heats the fluidized medium discharged from the gasification furnace and combusts residue of the gasification raw material; a medium separator that, in order to return the fluidized medium to the gasification furnace, separates the fluidized medium from a combustion exhaust gas discharged from the combustion furnace; a gasification gas separator that separates the gasification gas produced in the gasification furnace from the residue of the gasification raw material; and a residue discharge section that creates a seal between the gasification gas separator and the combustion furnace, and discharges the residue separated by the gasification gas separator into the combustion furnace. | 2014-11-06 |
20140328731 | DEVICE FOR INDUCING NUCLEATION - Described is a device for inducing crystal nucleation in a crystalliser. The device comprises a vessel for fluid and a surface abrader, wherein the surface abrader is configured to abrade a surface within the vessel to induce crystal nucleation. The friction of the abrader against the surface within the vessel creates nano-sized particulates which induce crystal nucleation. Crystal growth can then take place in the crystalliser. Also described is a crystallisation apparatus comprising the device and a crystallisation process using the device or similar. The device is significantly cheaper and more reliable than known ultrasound devices and facilitates the separation of crystal nucleation and crystal growth. The device also enables the avoidance of the use of seeding as a source of secondary nucleation. | 2014-11-06 |
20140328732 | Apparatus and Cartridge for Hemostasis Testing - A sample testing cartridge is usable to perform a variety of tests on a visco-elastic sample, such hemostasis testing on a whole blood or blood component sample. The cartridge includes a sample processing portion that is in fluid communication with a sample retention structure. A suspension, such as a beam, arm, cantilever or similar structure supports or suspends the sample retention portion relative to the sample processing portion in a unitary structure. In this manner, the sample retention portion may be placed into dynamic excitation responsive to excitation of the cartridge and correspondingly dynamic, resonant excitation of the sample contained within the sample retention portion, while the sample processing portion remains fixed. Observation of the excited sample yields data indicative of hemostasis. The data may correspond to hemostasis parameters such as time to initial clot formation, rate of clot formation, maximum clot strength and degree of clot lysis. | 2014-11-06 |
20140328733 | Simplified Gating Method for Sealing and Flow Control in Micro and Nano Devices - A biochip for multiplex genetic identification is disclosed. An biochip for separating and detecting a plurality of DNA fragments includes a set of inputs and chambers for receiving a sample matrix of genetic material and reagents needed to conduct a polymerase chain reaction amplification of the genetic material. The biochip also includes a plurality of separation and detection chambers that physically separate different DNA fragments that have been marked with labels that emit similar colors, thereby enabling the independent detection of the different DNA fragments. | 2014-11-06 |
20140328734 | Biological Specimen Collection and Storage Devices - A biological sample containment system and method are provided that include a container for storing the biological sample and an indicator affixed to the container for displaying at least one measured characteristics of the container or sample, wherein measurement of the characteristic is commenced by activation of the indicator. In yet another embodiment of the invention, a biological sample containment system and method are provided that include a container for collecting a biological sample and a label affixed to the container, wherein information relating to the biological sample or container is situated on the label and at least a portion of said information is situated on a face of the label that is affixed to the container. | 2014-11-06 |
20140328735 | CONTAINER FOR THE LABORATORY AREA AND METHOD FOR MARKING SUCH A CONTAINER - Container ( | 2014-11-06 |
20140328736 | METHOD FOR SEPARATION OF CHEMICALLY PURE OS FROM METAL MIXTURES - A method for separating an amount of osmium from a mixture containing the osmium and at least one other additional metal is provided. In particular, method for forming and trapping OsO | 2014-11-06 |
20140328737 | COBALT EXTRACTION METHOD - The objective of the present invention is to selectively extract cobalt from an acidic solution containing a high concentration of manganese. This cobalt extraction method extracts cobalt from an acidic solution containing manganese and cobalt by subjecting the acidic solution to solvent extraction by means of a valuable metal extraction agent comprising an amide derivative represented by general formula (I). The valuable metal extraction agent is represented by the general formula. In the formula: R | 2014-11-06 |
20140328738 | Catalyst for Treating Exhaust Gas - Provided is a metal promoted, low SAR zeolite-based SCR catalyst having at least about 1.35 weight percent of cerium, based on the total weight of the zeolite, wherein said cerium is present in a form selected from exchanged cerium ions, monomeric ceria, oligomeric ceria, and combinations thereof, provided that said oligomeric ceria has a particle size of less than 5 μm, the catalyst having superior durability after hydrothermal aging. | 2014-11-06 |
20140328739 | EMISSION CONTROL SYSTEM - A method and apparatus for treating an exhaust or waste gas stream using Silic Pollution Reduction System (SPRS) is provided to remove at least one unwanted material to clean the exhaust or waste gas stream by gas stabilisation to allow the cleaned gas stream to be discharged directly to atmosphere. The apparatus includes at least three treatment stations for treating the exhaust or waste gas stream in sequence, in which at least one treatment station is a wet reactor containing a nucleating or precipitating liquid for removing the unwanted material as a solid and for oxygenating the remaining gas stream from which the unwanted material has been removed, and at least one treatment station is or has a gas compressing stage or component for compressing the gas stream being treated. The advantage of the method and apparatus is that the treated gas stream can be discharged directly to atmosphere with reduced amounts of pollutants. | 2014-11-06 |
20140328740 | METHODS FOR PRODUCING SILANE - Methods and systems for producing silane that use electrolysis to regenerate reactive components therein are disclosed. The methods and systems may be substantially closed-loop with respect to halogen, an alkali or alkaline earth metal and/or hydrogen. | 2014-11-06 |
20140328741 | Silicon Photonic Fiber and Method of Manufacture - Methods of converting silica to silicon and fabricating silicon photonic crystal fiber (PCF) are disclosed. Silicon photonic crystal fibers made by the fabrication methods are also disclosed. One fabrication method includes: sealing silica PCF and a quantity of magnesium within a container, the quantity of magnesium defined by 2Mg | 2014-11-06 |
20140328742 | METHOD FOR PRODUCING GROUP III NITRIDE CRYSTAL, GROUP III NITRIDE CRYSTAL, AND SEMICONDUCTOR DEVICE - The present invention provides a method for producing a Group III nitride crystal, capable of producing a Group III nitride crystal in a large size with few defects and high quality. The method is a method for producing a Group III nitride crystal ( | 2014-11-06 |
20140328743 | REMOVING CARBON DIOXIDE FROM WASTE STREAMS THROUGH CO-GENERATION OF CARBONATE AND/OR BICARBONATE MINERALS - All of the methods and devices disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the methods and devices of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the methods and devices and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit, and scope of the invention. More specifically, it will be apparent that certain compositions which are chemically related may be substituted for the compositions described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope, and concept of the invention as defined by the appended claims. | 2014-11-06 |
20140328744 | CARBON NANOTUBES AND METHOD FOR MANUFACTURING THE SAME - Disclosed are carbon nanotubes and a method for manufacturing the same. Advantageously, the method provides a high yield of potato or sphere-shaped non-bundled carbon nanotubes having a bulk density of 80 to 250 kg/m | 2014-11-06 |
20140328745 | METHOD FOR PRODUCING CARBONACEOUS FILM AND METHOD FOR PRODUCING GRAPHITE FILM - Disclosed herein is a method for producing a roll-shaped carbonaceous film by polymer pyrolysis while suppressing the occurrence of fusion bonding in the roll-shaped carbonaceous film. The carbonaceous film production method includes the step of heat-treating a polymer film wound into a roll, wherein, at a temperature equal to or higher than the pyrolysis onset temperature of the polymer film but equal to or lower than a temperature at which the weight of the polymer film is reduced by 40% as compared to that before heat treatment, the roll-shaped polymer film has (2-1) a gap between layers of the polymer film so that a value determined for the whole roll-shaped polymer film by dividing the thickness of the gap between adjacent layers of the polymer film (Ts) by the thickness of the polymer film (Tf) (Ts/Tf) satisfies a relationship of 0.33≦Ts/Tf≦1.50 and/or (2-2) a space inside a 50% cross-sectional circle of the roll-shaped polymer film so that the area of the space inside the 50% cross-sectional circle is 25% or more of the cross-sectional area of the 50% cross-sectional circle. | 2014-11-06 |
20140328746 | ZIRCONIA SINTERED BODY, ZIRCONIA COMPOSITION AND ZIRCONIA CALCINED BODY, AND DENTAL PROSTHESIS - Zirconia sintered body having similar appearance to natural tooth. On straight line extending in first direction from one end to the other end of zirconia sintered body, when chromaticity (L*, a*, b*) by a L*a*b* colorimetric system of first point positioned in section from the one end to 25% of the whole length is (L1, a1, b1) and chromaticity (L*, a*, b*) by L*a*b* colorimetric system of second point positioned in section from the other end to 25% of whole length is (L2, a2, b2), L1 ranges from 58.0 to 76.0, a1 ranges from −1.6 to 7.6, b1 ranges from 5.5 to 26.3, L2 ranges from 71.8 to 84.2, a2 ranges from −2.1 to 1.8, b2 ranges from 1.9 to 16.0, L1a2, b1>b2, and tendency to increase or decrease chromaticity by the L*a*b* colorimetric system from first point to second point does not change. | 2014-11-06 |
20140328747 | ZINC OXIDE SPUTTERING TARGET AND METHOD FOR PRODUCING SAME - Provided is a zinc oxide sputtering target, which can effectively suppress the occurrence of break or crack in the target during sputtering to enable production of a zinc oxide transparent conductive film with high productivity. The zinc oxide sputtering target is composed of a zinc oxide sintered body comprising zinc oxide crystal grains, wherein the zinc oxide sputtering target has a sputter surface having a (100) crystal orientation degree of 50% or more. | 2014-11-06 |
20140328748 | HYDROGENATION AND DEHYDROGENATION CATALYST, AND METHODS OF MAKING AND USING THE SAME - The present application discloses complexes useful as catalysts for organic chemical synthesis including hydrogenation and dehydrogenation of unsaturated compounds or dehydrogenation of substrates. The range of hydrogenation substrate compounds includes esters, lactones, oils and fats, resulting in alcohols, diols, and triols as reaction products. The catalysts of current application can be used to catalyze a hydrogenation reaction under solvent free conditions. The present catalysts also allow the hydrogenation to proceed without added base, and it can be used in place of the conventional reduction methods employing hydrides of the main-group elements. Furthermore, the catalysts of the present application can catalyze a dehydrogenation reaction under homogenous and/or acceptorless conditions. As such, the catalysts provided herein can be useful in substantially reducing cost and improving the environmental profile of manufacturing processes for variety of chemicals. | 2014-11-06 |
20140328749 | USE OF A PROCESS FOR HYDROGEN PRODUCTION - The present invention relates to the use of a process for hydrogen production in which at least a part of a hydrocarbonaceous feed gas (a) is passed into a reformer (c), wherein the feed gas is contacted in the reformer with a catalyst and the feed gas is converted to hydrogen and solid carbon, for the direct production of a hydrogenous gas at filling stations for sale to a consumer, and also to a reactor (d) for hydrogen production. | 2014-11-06 |
20140328750 | Antibodies Reactive with B7-H3 and Uses Thereof - The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers. | 2014-11-06 |
20140328751 | ANTIBODIES THAT BIND OV064 AND METHODS OF USE THEREFOR - Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein. | 2014-11-06 |
20140328752 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 2014-11-06 |
20140328753 | Antibodies for Molecular Imaging of Vulnerable Plaques in Atherosclerosis - Antibodies for molecular imaging of vulnerable plaques in atherosclerosis Antibody specifically binding to atherosclerosis lesions for in vivo imaging and methods for in vivo imaging of atherosclerosis lesions in a patient. | 2014-11-06 |
20140328754 | RADIOACTIVE METAL-LABELED ANTI-CADHERIN ANTIBODY - A radioactive metal-labeled anti-cadherin antibody which is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent. | 2014-11-06 |
20140328755 | HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS AND RADIOLIGANDS AS PROBES IN NOCICEPTIVE PROCESSING AND THE PATHPHYSIOLOGICAL STUDY OF MEMORY DEFICITS AND COGNITIVE DISORDERS - A method for localizing and quantifying S1R role in nociceptive processing; for providing a guide to providing an analgesic therapy; of using an S1R selective ligand as a biomarker for pathphysiological study of memory deficits and cognitive disorders; or of detecting increased S1R density at the site of nerve injury arising from neuropathic pain comprising using as a probe at least one SR1 selective compound or radioligand of the general formula III′, or IV′: | 2014-11-06 |
20140328756 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS - The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in | 2014-11-06 |
20140328757 | COMPOSITIONS COMPRISING ASCORBIC ACID AND AN IMAGING AGENT AND RELATED METHODS - The present invention is generally directed towards compositions comprising ascorbic acid or ascorbate salt and an imaging agent, and related methods. In some embodiments, the imaging agent comprises pyridaben or a pyridaben analog attached to an imaging moiety. | 2014-11-06 |
20140328758 | USE OF FSH RECEPTOR LIGANDS FOR DIAGNOSIS AND THERAPY OF CANCER - The present invention relates to diagnostic imaging and in particular to the diagnostic imaging and therapy of cancer by means of compositions which specifically target the FSH Receptor expressed by tumor endothelial cells and circulating blood cells. | 2014-11-06 |
20140328759 | LIMIT SIZE LIPID NANOPARTICLES AND RELATED METHODS - Various lipid nanoparticles are disclosed, including nanoparticles comprising a lipid bilayer comprising a phospholipid, a sterol, a polyethylene glycol-lipid surrounding an aqueous core which comprises a therapeutic and/or diagnostic agent and nanoparticles comprising a lipid monolayer surrounding a hydrophobic core. Of particular interest are limit size lipid nanoparticles with a diameter from 10-100 nm. Such lipid nanoparticles are the smallest particles possible for a specific particle composition. Methods and apparatus for preparing such limit size lipid nanoparticles are disclosed. | 2014-11-06 |
20140328760 | ISOTOPIC LABELING OF HIGHER ORGANISMS - The invention generally relates to metabolic labeling of a target organism with a stable isotope. In a first aspect, the present invention relates to a method for metabolic labeling of a target organism with a stable isotope. The present invention also relates to a method of producing a diet for metabolic labeling of a target organism and to a diet composition for metabolic labeling of a target organism. In a further aspect the invention describes the use of the diet composition according to the present invention for producing a metabolically labeled target organism as a reference for a quantitative proteomic approach. The present invention also relates, in a further aspect, to the use of a diet composition for pulse SILAC labeling. The present invention also relates to the use of a target organism labeled by the method according to the first aspect of the present invention as a spike-in standard in quantitative proteomics approaches. | 2014-11-06 |
20140328761 | Local J-Coupling Dye-Zeolite Antenna Composite Materials - A dye loaded zeolite composite material comprises a plurality of zeolite crystals each having a plurality of straight through uniform channels extending between the proximal face and the distal face and having a channel axis parallel to and a channel width transverse to a longitudinal crystal axis A. Each channel contains a substantially linear arrangement of dye molecules comprising first and second dye molecules having an elongated shape with a longitudinal extension exceeding said channel width and a lateral extension not exceeding said channel width. Each dye molecule consists of a chromophore moiety arranged between a pair of terminal moieties, wherein: the chromophore moieties of the first and second dye molecules are substantially identical, the terminal moieties of the first dye molecules have a lateral extension larger than half of the channel width, the terminal moieties of the second dye molecules have a lateral extension smaller than half of the channel width, the linear arrangement of dye molecules comprises at least one pair of second dye molecules adjacent each other. | 2014-11-06 |
20140328762 | Fluorogenic Peptide Probes and Assays - Fluorogenic peptide probes specific for a target molecule are provided. Exemplary fluorogenic peptide probes include a peptide labeled with a fluorogenic label, wherein the fluorogenic peptide probe has an unstructured three dimensional conformation in the absence of the target molecule and a structured three dimensional conformation in the presence of the target polypeptide. The structured three dimensional conformation includes an alpha-helix that forms a coiled-coil with the target molecule allowing generation of a detectable signal from the fluorogenic label in response to an exciting amount of radiation. | 2014-11-06 |
20140328763 | BIOACTIVE AMPHIPHILIC POLYMER STABILIZED NANOPARTICLES WITH ENHANCED STABILITY AND ACTIVITY - The present invention relates to nanoparticle compositions and treatment of cardiovascular disease using nanoparticles to target Class A and B scavenger receptors. This invention further relates to methods of detecting cells that express scavenger receptors, detecting atherosclerotic lesions, and targeting bioactive amphiphilic macromolecules to cells that express scavenger receptors. | 2014-11-06 |
20140328764 | Biocompatible Nanoparticles with Aggregation Induced Emission Characteristics as Fluorescent Bioprobes and Methods of Using the Same for In Vitro and In Vivo Imaging - The development of fluorescent bioprobes comprising organic fluorescent compounds that exhibit aggregation induced emission (AIE) properties, methods of producing the same, and their practical applications for in vitro and in vivo bioimaging. | 2014-11-06 |
20140328765 | T1-T2 DUAL MODAL MRI CONTRAST AGENTS - The present invention relates a T1-T2 dual-modal MRI (magnetic resonance imaging) contrast agent, comprising (a) a first layer consisting of T1 contrast material; (b) a second layer consisting of T2 contrast material; and (c) a separating layer which is present in a space between the first layer and the second layer, and inhibits a reciprocal interference between T1 contrast material and T2 contrast material, and a heat-generating composition and a drug delivery composition having the same. The T1-T2 dual-modal contrast agent of the present invention may generate both T1 and T2 signal and thus observe the signal complementarily, resulting in accurate diagnosis through reduction of misdiagnosis. Further, T1 and T2 MR imaging may be simultaneously obtained by simple operation within the same MR imaging device, enabling to remarkably reduce a diagnosis time and diagnosis cost. In addition, the particle constituting the T1-T2 dual-modal contrast agent of the present invention may be applied to hyperthermia and drug delivery systems. | 2014-11-06 |
20140328766 | COMPOSITION AND METHOD FOR GENERATING A METABOLIC PROFILE USING 13C-MR DETECTION - The invention relates to a method of | 2014-11-06 |
20140328767 | METHOD AND DEVICE FOR PRODUCING OPTIMIZED LIPID-BASED MICRO/NANO-BUBBLES - A method of producing lipid-based micro/nano bubbles includes steps of (a) preparing a lipid mixture including one or more first lipids with different phase transition temperature, and a second lipid bonding with a hydrophilic polymer moiety or molecules capable of getting across a lipid membrane and decreasing van der Waals forces between lipid bilayers; (b) emulsifying the lipid mixture with a solvent, to form a transparent lipid carrier solution; (c) placing the transparent lipid carrier solution in a closed vessel with halo-substituted hydrocarbon; (d) manipulating temperature of the transparent lipid carrier solution to be close to a main phase transition temperature thereof; and (e) agitating in a mechanical manner the vessel containing the transparent lipid carrier solution to form micro/nano bubbles within the closed vessel. This method contributes to form micro/nano bubbles with desired diameters in a way of optimal material utilization efficiency. | 2014-11-06 |
20140328768 | Iron Oxide Nanocapsule, Method of Manufacturing the Same, and MRI Contrast Agent Using the Same - Provided is an iron oxide nanocapsule which has extremely excellent water dispersibility, which is very stable in the body and which has very excellent MRI contrast ability, a method of manufacturing the same, and an MRI contrast agent using the same. The method of manufacturing the iron oxide nanocapsule includes the steps of: thermally decomposing an iron complex to prepare hydrophobic ligand-bonded iron oxide nanoparticles; and encapsulating the hydrophobic ligand-bonded iron oxide nanoparticles by a carboxymethyldextrandodecylamine conjugate encapsulation material or a dextran-linoleic acid conjugate encapsulation material to form an iron oxide nanocapsule. | 2014-11-06 |
20140328769 | High Oil-Content Emollient Aerosol Foam Compositions - Described herein are high oil-content emulsions and compositions for the treatment of inflammatory skin disorders. The emulsions may be formulated as aerosol compositions. The aerosol propellant may be a hydrofluoroalkane propellant. The emulsions or compositions may comprise active agents, such as corticosteroids. Also described are methods of treating inflammatory skin disorders, comprising the step of applying to an affected area of a subject in need thereof a therapeutically-effective amount of an inventive emulsion or aerosol composition. | 2014-11-06 |
20140328770 | TOPICAL TETRACYCLINE COMPOSITIONS - A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force. | 2014-11-06 |
20140328771 | METHOD FOR PRODUCING 3-MENTHOXY PROPANOL AND COMPOSITIONS FOR IMPARTING COOLING SENSATION - [Problem] The present invention provides: a composition for imparting a cooling sensation, which contains 3-menthoxy propanol; and a method for producing 3-menthoxy propanol with high selectivity and high yield using 3-menthoxy-1,2-epoxypropane as a starting material. | 2014-11-06 |
20140328772 | SOLUBILIZED MAGNOLOL ANALOGS - A composition comprising a solubilized magnolol analog comprising at least one magnolol analog chosen from propyl magnolol, isopropyl magnolol, butyl magnolol, and isobutyl magnolol and a sorbitan ester. These solubilized analogs are useful in personal care, oral care, and home care compositions to provide anti -bacterial activity and reducing the expression of pro-inflammatory mediators. If isopropyl is selected, then the sorbitan ester is at least one of polyoxyethylene 20 sorbitan monooleate, and a proviso that if isobutyl magnolol is selected, then the sorbitan ester is poloxyethylene 20 sorbitan monooleate. | 2014-11-06 |
20140328773 | TOOTH-BLEACHING PREPARATIONS - The present invention relates to a tooth bleaching preparation comprising an adduct formulated from starting materials comprising peroxide, urea and an alkali metal polyphosphate, the adduct being provided in the preparation in aqueous conditions and the preparation having a pH in aqueous solution which rises on dilution of the solution. | 2014-11-06 |
20140328774 | OIL-IN-WATER SKIN CARE COMPOSITION - An oil-in-water emulsion skin care composition comprising from about 3% to about 25%, by weight of the composition, of a hydrocarbon oil or a mixture thereof, from about 2% to about 15%, by weight of the composition, of silicone particles or a mixture thereof, from about 0.1% to about 5%, of an emulsifier or a mixture thereof, and from about 30% to about 90%, by weight of the composition, of water. The composition provides a pleasing skin sensory without much affecting occlusivity. | 2014-11-06 |
20140328775 | Cosmetic Compositions and Methods For Inhibiting Melanin Synthesis - A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include batyl alcohol, undecylenoyl phenylalanine, hexyldecanol, and bisabolol. A method of reducing the synthesis of melanin by using the cosmetic compositions is also disclosed herein. | 2014-11-06 |
20140328776 | FILM FORMING PERSONAL CARE COMPOSITIONS AND METHODS - Compositions, kits and methods of preparing a biocompatible film for cosmetic or medical uses are disclosed. The compositions or kits contain polyvinyl acetal (PVA), siloxane and a solvent. The siloxane can have a hydrophilic group. Once the solvent content is reduced, for instance, by evaporation, the mixture of PVA and siloxane is solidified, forming a film. The compositions and kits, optionally, further include one or more of an antimicrobial agent, a pigment, an anti-inflammatory agent, an anesthetic agent or a hemostatic agent. Such a film can be used, for example, in the form of an antimicrobial sealant, a liquid bandage, body paints, scar camouflage, water-proof sun block, makeup sealer, or antimicrobial wipe or spray. | 2014-11-06 |
20140328777 | SUNSCREENS - The present invention relates to a composition for topical application comprising at least a benzotriazol derivative, at least one organic UV-filter substance and a cosmetic solvent selected from the group of benzoate solvents such as C | 2014-11-06 |
20140328778 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis - The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis. | 2014-11-06 |
20140328779 | COSMETIC PRODUCT CONTAINING FILM-FORMING POLYMER - A cosmetic product comprising a polymer having recurring units of formula (1): | 2014-11-06 |
20140328780 | COSMETIC COMPOSITIONS COMPRISING LATEX FILM FORMERS - Disclosed are cosmetic compositions comprising latex film formers chosen from at least one random styrene acrylate copolymer or derivatives thereof, and at least one acrylate copolymer or derivatives thereof, in combination with at least one coalescent and/or plasticizer. Also disclosed are cosmetic compositions comprising at least one latex film forming blend comprising (1) at least one random styrene acrylate copolymer and at least one acrylate copolymer or derivative thereof, or (2) at least two random styrene acrylate copolymers. Polyurethane latex dispersions may be incorporated into the compositions. Optionally, the cosmetic compositions may additionally comprise at least one coalescent and/or plasticizer in combination with the at least one latex film forming blend. | 2014-11-06 |
20140328781 | COSMETIC COMPOSITION COMPRISING AN UREA OR AMIDE BASED ALPHA-ALKOXYSILANE - The invention relates to a cosmetic composition, in particular a composition for making up and/or caring for keratin materials, preferably a nail makeup, comprising the compound of chemical formula (I) below: (I) in which: m represents an integer equal to 0 or 1; n represents an integer between 2 and 8; R1 represents a group (C | 2014-11-06 |
20140328782 | PEPTIDE INHIBITING MATRIX METALLOPROTEANASES ACTIVITY AND USE THEREOF - The present invention relates to a peptide inhibiting a matrix metalloproteanases activity and use thereof. The peptide inhibiting a matrix metalloproteanases activity exhibits an excellent efficacy of improving the condition of skin by directly inhibiting the matrix metalloproteanases activity. In addition, a composition containing the peptide of the invention has excellent bioactivities of inhibiting the activity of hyaluronic acid degrading enzymes, adipogenesis in fat cells, angiogenesis, and the like, thereby being useful for the treatment of various disease such as anti-obesity, anti-cancer, anti-inflammation, and the like, and skin permeability is excellent due to the small size of the peptide, thereby being useful in various fields. The peptide of the invention having excellent activity and safety can be advantageously applied to drugs, quasi-drugs, and cosmetics. | 2014-11-06 |
20140328783 | COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR COMPOUND CAPABLE OF ESTABLISHING HYDROGEN BONDS, AND TWO PARTICULAR DISTINCT SILICONE OILS - The present invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium, at least: (a) a supramolecular compound that may be obtained by reaction between: —at least one oil bearing at least one nucleophilic reactive function chosen from OH and NH | 2014-11-06 |
20140328784 | Hair Conditioning Cosmetic Compositions Containing A Mixture Of Amidoamines - Compositions are provided and described herein which include cosmetic and hair conditioning compositions having a mixture of stearamidopropyl dimethylamine and behenamidopropyl dimethylamine. Also provided are methods for conditioning hair using such mixtures. | 2014-11-06 |
20140328785 | COSMETIC COMPOSITION FOR COATING KERATIN FIBRES - The present invention relates to a cosmetic composition for coating keratin fibres of the emulsion type, comprising: an aqueous phase, at least one wax, an emulsifying system comprising: i) at least one C | 2014-11-06 |
20140328786 | COSMETIC COMPOSITION FOR COATING KERATINOUS FIBRES - The present invention relates to a cosmetic composition for coating keratinous fibres of the emulsion type, comprising: —an aqueous phase, —at least one wax, and —an emulsifying system comprising: i) at least one anionic surfactant in the salt form, ii) at least one cationic counterion, and iii) at least one basic amino acid, in which the total content of basic amino acid(s) and the total content of anionic surfactant(s) in the salt form are such that the ratio by weight of the basic amino acid(s) to the anionic surfactant(s) in the salt form is greater than or equal to 0.05. The present invention also relates to a method for coating keratinous fibres. | 2014-11-06 |
20140328787 | HAIR CARE COMPOSITION WITH SELECTED CATIONIC ALKYL OLIGOGLUCOSIDES AND OTHER QUATERNARY AMMONIUM COMPOUNDS - Hair treatment compositions include an active ingredient combination including selected cationic alkyl oligoglucosides and quaternary ammonium compounds as care agents.f | 2014-11-06 |
20140328788 | Curing Accelerator and Method of Making - A sterilized cyanoacrylate adhesive composition including a cyanoacrylate composition and a cure speed enhancer, wherein the sterilized cyanoacrylate adhesive composition does not cure upon sterilization. A kit for applying the sterilized cyanoacrylate adhesive composition, including the cyanoacrylate adhesive composition and an applicator. A method of making the sterilized cyanoacrylate adhesive composition, by adding a cure speed enhancer to a cyanoacrylate adhesive composition and sterilizing the composition. A method of applying the sterilized cyanoacrylate adhesive composition to tissue by applying the sterilized cyanoacrylate adhesive composition as a liquid, and quickly curing the sterilized cyanoacrylate adhesive composition. A method of sealing tissue by applying the sterilized cyanoacrylate adhesive composition as a liquid to tissue to be sealed, quickly curing the sterilized cyanoacrylate adhesive composition, and sealing the tissue. | 2014-11-06 |
20140328789 | pH-RESPONSIVE CELL SCAFFOLD AND METHOD OF USING SAME - A pH-responsive cell scaffold for growing a cell culture is disclosed. The cell scaffold has pores in which biological cells may be disposed. As the pH of the local environment drops, the cell scaffold swells to draw in additional oxygen and/or other nutrients. The increased supply of oxygen and/or nutrients increases the longevity of the cells. In some embodiments, the cell scaffold induces a change in gene expression that promotes wound healing. | 2014-11-06 |
20140328790 | SUSTAINED RELEASE PREPARATION COMPRISING INSECT PEST-TARGETING GEL COMPOSITION - Provided is a sustained release preparation comprising an insect pest-targeting gel composition, the preparation being free from leakage or reaction of a volatile substance and being capable of releasing the volatile substance at a constant rate. More specifically, provided is a sustained release preparation including a polymer tube and an insect pest-targeting gel composition in the polymer tube, the composition including one or more volatile substances and an oil gelling agent, wherein the volatile substances are included in an amount of from 70.0 to 99.0% by weight by the insect pest-targeting composition and are released outside of the polymer tube through the polymer tube. | 2014-11-06 |
20140328791 | Conjugates of an IL-2 Moiety and a Polymer - Conjugates of an IL-2 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties. | 2014-11-06 |
20140328792 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING VIRAL INFECTIONS - A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect. | 2014-11-06 |
20140328793 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS - Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient. | 2014-11-06 |
20140328794 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention. | 2014-11-06 |
20140328795 | VIRUCIDAL SMALL MOLECULE AND USES THEREOF - In an embodiment of the present disclosure there is provided a method of inactivating enveloped DNA virus particles in a biological sample. In an embodiment, such a method comprises contacting the biological sample with an effective amount of an antiviral composition comprising PD 404,182 In some embodiments, the DNA virus is the Herpes Simplex virus-1 (HSV-1) or the Herpes Simplex Virus-2 (HSV-2). In another embodiment of the present disclosure, there is provided a method of treating, preventing, or reducing a viral infection caused by an enveloped DNA virus in a subject in need thereof. In yet another embodiment, there is provided a method of preventing transmission of a viral infection to a subject in need thereof. In an embodiment, such a method comprises contacting a mucus membrane of the subject with a topical formulation comprising an effective amount of PD 404,182 in combination with a pharmaceutically acceptable carrier | 2014-11-06 |
20140328796 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I | 2014-11-06 |
20140328797 | HUMAN RHINOVIRUS (HRV) ANTIBODIES - The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis. | 2014-11-06 |
20140328798 | Co-Administration of a Parvovirus and a Cytokine for Therapy of Pancreatic Cancer - The present invention relates to a combination of a parvovirus and a cytokine, preferably IFNγ, for use in treating pancreatic cancer, in particular a terminal stage of this disease. | 2014-11-06 |
20140328799 | COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES - The present invention is directed to compositions comprising inhibitors of hepatitis C virus (HCV) protease and one or more additional therapeutically effective agents. Uses of such compositions as HCV inhibitors and methods of treating infection by HCV by administration of such compositions are also disclosed. | 2014-11-06 |
20140328800 | METHOD FOR THE BIOLOGICAL CONTROL OF LISTERIA - The invention relates to a method for controlling the proliferation of | 2014-11-06 |
20140328801 | ACCUMULATION OF METABOLIC PRODUCTS IN BACTERIAL MICROCOMPARTMENTS - A non-therapeutic method of accumulating a polymeric or high molecular weight molecular product within a bacterial microcompartment in bacterial cytoplasm, which method employs a recombinant bacteria which is transformed to express a microcompartment containing an enzyme capable of converting a low molecular weight substrate into a polymeric or high molecular weight product, the method comprising the steps of: incubating the recombinant bacteria with the low-molecular weight substrate, or a precursor of the low molecular weight substrate which is capable of being metabolised to the substrate within the recombinant bacteria, such that the substrate or precursor is taken up by the bacteria, wherein the substrate enters the microcompartment and the enzyme within the microcompartment converts the substrate to a polymeric or high molecular weight molecular product, and wherein the polymeric or high molecular weight molecular product is accumulated within the microcompartment due to its size. | 2014-11-06 |
20140328802 | Novel Strain of Lactobacillus Mucosae - The invention relates to a new strain of | 2014-11-06 |
20140328803 | Compositions and Methods - Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health. | 2014-11-06 |
20140328804 | Method for Treating or Preventing Graft Versus Host Disease - A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject. | 2014-11-06 |
20140328805 | BIHETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R | 2014-11-06 |
20140328806 | ENERGETIC THREE-DIMENSIONAL ARTIFICIAL CARDIAC PATCH AND USES THEREOF - In some embodiments, the present disclosure provides a method for fabricating a three-dimensional artificial cardiac patch construct. In some embodiments, such method includes the steps of coating a substrate with an organic polymer; allowing the organic polymer coating to air dry; mounting anchors on the organic polymer coating; and sterilizing the organic polymer coating and the anchors. In further embodiments, the method includes the steps of forming a biodegradable gel-based support scaffold on top of the organic polymer coating and seeding the biodegradable gel-based support scaffold with neonatal cardiac cells. In yet further embodiments, the method comprises culturing the neonatal cardiac cells in vitro to form a real cardiac layer, under culture conditions that are suitable for the cells to self-organize into a monolayer and detach from the substrate to form the three-dimensional cardiac patch. In some embodiments, the present disclosure pertains to a method of treatment of cardiac tissue injury in a subject in need thereof. In some embodiments, the method includes implanting the three-dimensional artificial cardiac patch described above in the injured area of the subject. In another embodiment the present disclosure provides a composition comprising the three-dimensional artificial cardiac patch described above. Additional embodiments of the present disclosure pertain to a medicament including the three-dimensional artificial cardiac patch described above. | 2014-11-06 |
20140328807 | Mesenchymal Stem Cells and Uses Therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 2014-11-06 |
20140328808 | TECHNIQUE FOR ISOLATING/CULTURING COLORECTAL EPITHELIAL STEM CELL, AND TECHNIQUE FOR TRANSPLANTING COLORECTAL EPITHELIUM EMPLOYING SAID TECHNIQUE - It is an object of the present invention to provide a culture medium for in vitro culture of a colorectal epithelial stem cell or the like, a method of in vitro culturing a colorectal epithelial stem cell or the like using the culture medium, a prophylactic or therapeutic agent for a bowel disease containing a colorectal epithelial stem cell or the like cultured by the method, a method of administrating, i.e., transplanting a colorectal epithelial stem cell or the like cultured by the method to a bowel disease patient, and a method of isolating a colorectal epithelial stem cell or the like. The culture medium for in vitro culture of a colorectal epithelial stem cell and/or a colorectal epithelial cell characteristically contains serum albumin, Wnt3a, and r-spondin-1. | 2014-11-06 |
20140328809 | METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS - The present invention relates to methods for enhancing differentiation of mesenchymal stem cells into chondrocytes and/or inducing chondrogenesis. The invention also relates to applications in the treatment of diseases which can affect cartilage (chondrodystrophies). The present invention also relates to methods of treatment comprising establishing a population of chondrocytes from a population of mesenchymal stem cells, which have been induced to differentiate with a synthetic triterpenoid, and administering the population of cells to a patient. | 2014-11-06 |
20140328810 | CELL-BASED THERAPY FOR THE PULMONARY SYSTEM - Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects. | 2014-11-06 |
20140328811 | METHOD FOR IMPROVING THE SUCCESS RATE OF HEMATOPOIETIC STEM CELL TRANSPLANTS - The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the genes encoding negative regulators of MHC expansion (e.g. AhR, Itch, Prox1 and/or SH2B3), and methods of using such dsRNA compositions to inhibit expression of negative regulators of MHC expansion. The use of such compositions to provide, for example, enhanced quantitites and/or qualities of MHCs and/or hematopoietic progenitor cells for transplantation and/or to enhance engraftment of transplanted MHCs hematopoietic progenitor cells is described. | 2014-11-06 |
20140328812 | CHIMERIC RECEPTORS WITH 4-1BB STIMULATORY SIGNALING DOMAIN - The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use. | 2014-11-06 |
20140328813 | Combination Bacteriolytic Therapy for the Treatment of Tumors - Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity. | 2014-11-06 |
20140328814 | ANTIMICROBIAL AND ANTIHYPERTENSIVE PROBIOTIC COMPOSITION, FOOD PRODUCT AND DIETARY SUPPLEMENT COMPRISING MICROORGANISM STRAIN LACTOBACILLUS PLANTARUM TENSIA DSM 21380 AND METHOD FOR SUPPRESSING CONTAMINATING MICROBES IN A FOOD PRODUCT - The present invention relates to an antimicrobial and antihypertensive probiotic compositions comprising microorganism strain | 2014-11-06 |
20140328815 | Lactic Acid Bacteria And Their Use As Dietary Supplementals For Poultry - Methods and compositions are hereby disclosed for enhancing weight gain and feed efficiency in a bird, such as a chicken, a turkey, or a laying hen, among others. The methods include administering to the bird a lactic acid producing bacterium (LAB) or combination of LABs. The disclosed methods and compositions also help reduce pathogen infection in the bird and reduce incidence of pathogen contamination in eggs produced by laying hens. | 2014-11-06 |
20140328816 | PACKAGED PROBIOTIC COMPOSITION AND USES THEREOF - The present invention relates to a packaged probiotic composition which is useful for treating or preventing bacterial colonisation in wounds and tissue. A characteristic feature of the invention is that the probiotic composition contains a probiotic microorganism which is in direct contact with water during storage of the probiotic composition. The invention furthermore pertains to methods of using and producing the probiotic composition. | 2014-11-06 |
20140328817 | COMPOSITION FOR OBTAINING BIOLOGICAL INSECTICIDE COMPRISING STRAINS OF BACILLUS THURINGIENSIS - The invention refers to formulae for biologic control of insect plagues in plants, free of chemicals, that include deposited | 2014-11-06 |
20140328818 | Proteases for Degrading Gluten - Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance. | 2014-11-06 |
20140328819 | COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions. | 2014-11-06 |
20140328820 | Novel Class of Therapeutic Protein Based Molecules - The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy. | 2014-11-06 |
20140328821 | VECTORS ENCODING ROD-DERIVED CONE VIABILITY FACTOR - The present invention relates to nucleic acids coding for and capable of expressing a rod-derived cone viability factor (RdCVF) and viral vectors containing these nucleic acids. The invention also relates to compositions and pharmaceutical preparations comprising these nucleic acids or vectors, methods of producing or secreting an RdCVF, and methods of treatment. | 2014-11-06 |
20140328822 | METHOD FOR PREPARING HIGHLY CONCENTRATED FIBRINOGEN SOLUTION AND METHOD FOR PREPARING FIBRIN SEALANT BY USING THEREOF - A method for preparing a highly concentrated fibrinogen solution includes adding amino acid or amino acid derivatives, and/or salts to a lowly concentrated fibrinogen solution, followed by a ultra-filtration concentration. Factor XIII can be added either before or after the ultra-filtration to give a fibrin sealant component | 2014-11-06 |
20140328823 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer - The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer. | 2014-11-06 |
20140328824 | Diagnostic and Therapeutic Methods and Their Application in Amyotrophic Lateral Sclerosis (ALS) - The present invention provides a method of treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject, the method comprising administering to a subject an agent, which interferes with IgG-A2BG2 expression, IgG-A2BG2 function or IgG-A2BG2 interaction with CD16 in said subject. | 2014-11-06 |
20140328825 | MAKING AND USING IN VITRO-SYNTHESIZED ssRNA FOR INTRODUCING INTO MAMMALIAN CELLS TO INDUCE A BIOLOGICAL OR BIOCHEMICAL EFFECT - The present invention relates to compositions, kits and methods for making and using RNA compositions comprising in vitro-synthesized ssRNA inducing a biological or biochemical effect in a mammalian cell or organism into which the RNA composition is repeatedly or continuously introduced. In certain embodiments, the invention provides compositions and methods for changing the state of differentiation or phenotype of a human or other vertebrate cell. For example, the present invention provides mRNA and methods for reprogramming cells that exhibit a first differentiated state or phenotype to cells that exhibit a second differentiated state or phenotype, such as to reprogram human somatic cells to pluripotent stem cells. | 2014-11-06 |
20140328826 | PRODUCT AND METHOD FOR TREATING KELOID SCARS, HYPERTROPHIC SCARS AND BURN SCARS WITH CONTRACTURE - A method of treating keloid scars, hypertrophic scars or burn scars with contracture includes administering low molecular weight hyaluronic acid to the keloid scar, hypertrophic scar or burn scar with contracture. | 2014-11-06 |
20140328827 | Methods for Fucoidan Purification from Seaweed Extracts - Methods for purifying fucoidan in extracts from brown seaweed are disclosed. In particular, methods of purifying fucoidan in the extract to remove heavy metal ions, bacterial and endotoxin contaminants, and other impurities are disclosed. The methods include the use of a chelating agent, selective precipitation, and filtration. | 2014-11-06 |